Evaluating the Efficacy and Safety of Erenumab (AMG 334) In Chronic Migraine Prevention in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study (S52.002)

Conclusions:Erenumab 70 mg and 140 mg were efficacious in patients with CM and had a safety profile similar to placebo.Study Supported by: Amgen Inc.Disclosure: Dr. Tepper has received personal compensation for activities with Acorda, Alder, Allergan, Amgen, ATI, Avanir, Dr. Reddy's, eNeura, Pfizer, Scion Neurostim, Teva, Zosana, Depomed, Impax, Pernix, Teva, Amgen, and Merck. Dr. Tepper has received personal compensation in an editorial capacity for Headache Currents. Dr. Tepper holds stock and/or stock options in ATI. Dr. Tepper has received research support from Alder, Allergan, Amgen, ATI, Scion Neurostim, Teva, Zosano. Dr. Widnell has received personal compensation for activities with Amgen as an employee. Dr. Dolezil has nothing to disclose. Dr. Ashina has received research support from ATI and Amgen. Dr. Reuter has received personal compensation for activities with Amgen, Co-Lucid, Pharm-Allergan, Electrocore, and Autonomic Technologies. Dr. Brandes has received personal compensation for activities with Avanir, Supernus, Teva, Depomed, Pernix, and Amgen as a speaker, consultant or advisory board member. Dr. Silberstein has received research support from Allergan, Inc., Amgen, Cumberland Pharmaceuticals, Inc., ElectroCore Medical, LLC., Labrys Biologics, Eli Lilly and Company, and Merz. Dr. Winner has received personal compensation for activities with Avanir, Allergan, Teva, and Supernus. Dr. Winner has received personal compensation in an editorial capacity for Headach...
Source: Neurology - Category: Neurology Authors: Tags: Headache: Clinical Trials and Disease Burden Source Type: research